Stockreport

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio [Yahoo! Finance]

Design Therapeutics, Inc.  (DSGN) 
PDF Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Cash and Securities of $261.0 Million Supports Ope [Read more]